The Institute for Neurophysiopathology spinout has completed a series D round.

Vect-Horus, a France-based biotechnology developer spun out of Institute for Neurophysiopathology, has completed a €12m ($14.5m) series D round featuring undisclosed backers.
Vect-Horus is working on vectors that enable therapeutic molecules or imaging agents to be delivered to key organs. The money has been allocated to existing programmes, the development of additional vectors and technology validation.
The company emerged out of Institute for Neurophysiopathology, a joint research institute of Aix Marseille University and CNRS. It was founded in 2005.
Vect-Horus had obtained a total of €22m in equity and grant funding as of mid-2018.
CAAP Création, a subsidiary of Crédit Agricole Alpes Provence, Financière Tuileries Co-Invest and SCR Provençale et Corse, a subsidiary of Banque Populaire Méditerranée, supplied $4.2m in funding in June 2018. Unnamed investors had injected $3m in 2017.

Thierry Heles

Thierry Heles is the former editor-at-large of Global University Venturing and Global Corporate Venturing, and was the producer and host of the Beyond the Breakthrough podcast until December 2024.